Fusion IP

Extraject Technology is provides research and experimental development on natural sciences and engineering.

Exonate is a biotechnology company focused on developing small molecule drugs that modulate alternative messenger RNA splicing. It specializes in ophthalmology, with a primary focus on treating diabetic retinopathy and diabetic macular oedema (DMO), as well as wet age-related macular degeneration (wAMD). The company's lead program aims to provide superior efficacy through topical agents in preclinical models of wAMD.

Absynth Biologics Limited is a biotechnology company focused on discovering and developing vaccines and therapeutic antibodies aimed at preventing and treating bacterial infections. Founded in 2007 and based in Alderley Edge, United Kingdom, the company targets significant pathogens, including Staphylococcus aureus, Clostridium difficile, and Streptococcus pyogenes. Utilizing a platform that identifies novel protein antigen targets, Absynth Biologics employs a dual-action mechanism that combines direct antibacterial activity through antibody-mediated effects and the engagement of immune effector functions to eliminate bacteria. By characterizing specific proteins from these bacteria as immunological targets, the company aims to enhance patient immunity and address serious health threats associated with bacterial infections.

Magnomatics Limited is a technology engineering company based in Sheffield, United Kingdom, founded in 2006 as a spin-out from the University of Sheffield. Specializing in proprietary magnetic gear technology, Magnomatics develops innovative products such as the Pseudo Direct Drive, a high torque low-speed motor and generator suitable for various applications including actuation, fan motors, marine propulsion, and wind power. Additionally, the company offers MAGSPLIT, a power-split continuously variable transmission solution designed for blended hybrid powertrains and ancillary drives. Serving diverse sectors such as oil and gas, automotive, aerospace, marine propulsion, renewable energy, and rail traction, Magnomatics aims to provide efficient alternatives to traditional mechanical gears, thereby lowering operating costs and reducing carbon emissions in the transport and energy industries.

Nanotether Discovery Science Ltd, established in 2012 and headquartered in Cardiff, UK, specializes in developing innovative technology platforms for life science research. The company focuses on accelerating drug discovery by miniaturizing and expediting the study of interactions between proteins and drug candidates, using variable-length DNA molecules as tethers. This approach significantly reduces material requirements and enhances throughput, catering to the needs of high-throughput drug discovery programs in the pharmaceutical and biotechnology sectors. As of 2017, the company operates as a subsidiary of Belluscura Ltd.

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

Phase Focus Limited is a technology company based in Sheffield, United Kingdom, specializing in lensless microscopy solutions. Founded in 2006, the company has developed a proprietary process that utilizes a novel iterative phase retrieval algorithm to produce high-definition images without the need for high-quality lenses. Its flagship product, Livecyte, measures cell growth and cell cycle duration, offering valuable insights for applications in wound healing, oncology, toxicology, angiogenesis, and stem cell research. Additionally, Phase Focus provides the VL21 live cell imaging solution, which enables non-toxic phenotypic screening for live cells and facilitates long-term time-lapse assays. The company also offers a lens profiler system that delivers quantitative data on the performance, safety, and comfort of hydrated soft contact lenses, along with contact lens measurement services. Furthermore, its Πbox serves as a diffractive image reconstruction engine for ptychographic processing across multiple wavelengths, enhancing the capabilities of optical, X-ray, and electron microscopy.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Zilico develops medical diagnostic devices using electrical impedance spectroscopy technology. Its primary product, ZedScan, enhances cervical cancer diagnosis by providing real-time, objective assessments alongside colposcopy.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Seren Photonics Limited specializes in the development and manufacture of semi-polar and non-polar Gallium Nitride (GaN) templates, which are essential for light-emitting diodes (LEDs), lasers, vertical-cavity surface-emitting lasers (VCSELs), and power switches. Based in Bridgend, United Kingdom, the company employs a proprietary manufacturing process to produce these templates, specifically growing semi-polar GaN on m-plane sapphire and non-polar GaN on r-plane sapphire. Their innovative technology significantly enhances light intensity in high-brightness LEDs, achieving increases in light generation ranging from 100% to 900% compared to untreated diodes. Founded in 2009, Seren Photonics has positioned itself to serve various lighting markets, including backlighting for laptops and televisions, signage, and architectural lighting. As of November 2016, it operates as a subsidiary of Fusion IP Sheffield Limited.

Seren Photonics Limited specializes in the development and manufacture of semi-polar and non-polar Gallium Nitride (GaN) templates, which are essential for light-emitting diodes (LEDs), lasers, vertical-cavity surface-emitting lasers (VCSELs), and power switches. Based in Bridgend, United Kingdom, the company employs a proprietary manufacturing process to produce these templates, specifically growing semi-polar GaN on m-plane sapphire and non-polar GaN on r-plane sapphire. Their innovative technology significantly enhances light intensity in high-brightness LEDs, achieving increases in light generation ranging from 100% to 900% compared to untreated diodes. Founded in 2009, Seren Photonics has positioned itself to serve various lighting markets, including backlighting for laptops and televisions, signage, and architectural lighting. As of November 2016, it operates as a subsidiary of Fusion IP Sheffield Limited.

MedaPhor Limited is an e-learning company based in Cardiff, United Kingdom, that specializes in creating training products for postgraduate medical professionals. The company focuses on enhancing ultrasound examination techniques through its innovative simulation technology solutions. MedaPhor's offerings include Blue Phantom, which provides ultrasound phantoms for hands-on simulation training in gynaecology and obstetrics, and True Anatomy, an endovaginal training model designed for ultrasound simulation. Additionally, MedaPhor develops models for intrauterine pregnancy, ectopic pregnancy, and general pathology, contributing to the advancement of medical education and training. Established in 2004, MedaPhor aims to improve the skills and knowledge of healthcare practitioners through its comprehensive training solutions.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Morvus Technology Ltd is a UK-based pharmaceutical company focused on discovering, developing, and commercializing oncology drugs. It specializes in radiosensitizers like MTL-005 for head and neck cancer, and pro-tide technologies such as MTL-007 to enhance established chemotherapeutics' therapeutic index.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Mesuro is a technology company specializing in radio frequency equipment and device measurement solutions for the semiconductor industry. Founded on over a decade of research at Cardiff University's Institute of High Frequency and Communication's Engineering, Mesuro collaborates with leading companies in the RF communications sector to tackle significant technical challenges. The company provides device modeling, characterization, and optimization test services aimed at enhancing the performance of RF and microwave devices and amplifiers, thereby supporting advancements in design and manufacturing processes.

Diurnal Group plc is a specialty pharmaceutical company based in Cardiff, United Kingdom, that specializes in developing hormone therapeutics for the treatment of chronic endocrine conditions. Founded in 2004, the company aims to provide innovative solutions for conditions such as congenital adrenal hyperplasia, adrenal insufficiency, hypogonadism, and hypothyroidism. Diurnal's notable products include Alkindi, a replacement therapy for pediatric adrenal insufficiency, and Chronocort, which has completed Phase III clinical trials for adrenal insufficiency and congenital adrenal hyperplasia. The company is also advancing its early-stage pipeline with products such as Native Oral Testosterone for hypogonadism, a siRNA therapy for adrenocorticotropin-dependent Cushing's syndrome, and a modified-release preparation of T3 hormone for hypothyroidism. Diurnal's research emphasizes circadian-based endocrinology, focusing on physiological treatment regimes to address the needs of patients with rare and chronic endocrine disorders.

Phase Focus Limited is a technology company based in Sheffield, United Kingdom, specializing in lensless microscopy solutions. Founded in 2006, the company has developed a proprietary process that utilizes a novel iterative phase retrieval algorithm to produce high-definition images without the need for high-quality lenses. Its flagship product, Livecyte, measures cell growth and cell cycle duration, offering valuable insights for applications in wound healing, oncology, toxicology, angiogenesis, and stem cell research. Additionally, Phase Focus provides the VL21 live cell imaging solution, which enables non-toxic phenotypic screening for live cells and facilitates long-term time-lapse assays. The company also offers a lens profiler system that delivers quantitative data on the performance, safety, and comfort of hydrated soft contact lenses, along with contact lens measurement services. Furthermore, its Πbox serves as a diffractive image reconstruction engine for ptychographic processing across multiple wavelengths, enhancing the capabilities of optical, X-ray, and electron microscopy.

Abcellute is to achieve global adoption of its SureCellâ„¢ cell transport technology by providing the research community with enhanced, fresh-cell systems. These will maximise the utilisation of this often scarce resource and provide products that are much more convenient to use than current fresh-cell systems. This will deliver benefits to biomedical researchers in key areas such as pre-clinical drug evaluation and regenerative medicine.

Medella Therapeutics, a spinout company from the University of Sheffield, is developing new cancer treatments using monoclonal antibodies – proteins made by the immune system that bind to a single target, such as a cancer cell – that have fewer side effects than many other therapies.

Asterion Ltd. is a biopharmaceutical company based in Sheffield, United Kingdom, that specializes in developing innovative therapeutic proteins aimed at treating both chronic and acute disorders. Founded in 2000, Asterion focuses on creating patient-friendly drugs that leverage patented technologies to provide long-acting, potent biopharmaceuticals. Their product pipeline includes growth hormone agonists for growth disorders, growth hormone antagonists for acromegaly, AFT-erythropoietin for anemia, and AFT-granulocyte colony stimulating factor for neutropenia. These advancements are designed to enhance healthcare outcomes by improving efficacy, minimizing side effects, and increasing patient compliance while reducing the frequency of drug administration compared to currently marketed alternatives. Asterion was previously a subsidiary of Fusion IP Sheffield Limited.

CellTran Limited engages in the research and development of products for the regeneration of tissue and the healing of wounds. The company offers Myskin that is used for the treatment of difficult to heal wounds; Lyphoderm, a freeze-dried lysate from cultured human keratinocytes that is formulated into a hydrophilic gel; and Ulcodress, an integrated wound care dressing that provides control of moisture, infection, and proteases within the wound area. It provides skin banking services, as well as contract manufacture services in the fields of materials fabrication and cell culture. The company was founded in 2000 and is based in Sheffield, the United Kingdom. As of October 28, 2008, CellTran Limited operates as a subsidiary of York Pharma plc.